Interactive demonstration · synthetic data
Laboratory result.
A received blood panel for a patient on methotrexate. It evidences an open monitoring item and carries a laboratory flag for clinician review.
Each scenario has its own address, and the address keeps your place, so you can share it or come back to it. Reset at any time.
Step 1 of 3 Open an item to see the passage it came from, then accept, edit or reject it. 0 of 2 decided.
Source document
Numbers mark the passages each item cites.Full blood count1
| Test | Result | Reference range | Flag |
|---|---|---|---|
| Haemoglobin | 128 g/L | 115–165 | |
| White cell count | 6.1 ×10⁹/L | 4.0–11.0 | |
| Neutrophils | 3.8 ×10⁹/L | 2.0–7.5 | |
| Platelets | 251 ×10⁹/L | 150–400 |
Liver function1
| Test | Result | Reference range | Flag |
|---|---|---|---|
| ALT2 | 62 U/L | 0–40 | H |
| ALP | 84 U/L | 30–130 | |
| Bilirubin | 9 µmol/L | 0–21 | |
| Albumin | 41 g/L | 35–50 |
Urea and electrolytes1
| Test | Result | Reference range | Flag |
|---|---|---|---|
| Sodium | 139 mmol/L | 133–146 | |
| Potassium | 4.4 mmol/L | 3.5–5.3 | |
| Creatinine | 71 µmol/L | 45–84 | |
| eGFR | 81 mL/min/1.73m² |
Laboratory comment
ALT above reference range.2 Please interpret in the clinical context.
Open work and proposed work 3
Each item shows the findings and the exact passages it comes from. Open one to decide on it.
Item 1 of 3: Monitoring dueMethotrexate monitoring bloods: FBC, LFT, U&EVerified
From the document
- Linked requestLinked to open work
Requested for methotrexate monitoring
Record Open item: methotrexate monitoring bloods (FBC, LFT, U&E) due 13 Oct, assigned to the admin team.
Why Reedley says this The clinical details on the request match an open monitoring item for this patient.
- Panels received
FBC, LFT and U&E all reported
All three requested panels are present, so this report can evidence the open item.
Why Reedley says this Each panel named in the monitoring item appears in the report.
Open work this document affects
Evidence in this document Pathology: FBC, LFT and U&E received 14 Oct 2026 09:12 for this patient (this report). (Simulated) The monitoring bloods were taken and reported.
Verified when: All three panels received for this patient within the window. Source: Pathology, by design; simulated here.
Limit A received result is not a reviewed result. The laboratory flag goes to a clinician as its own item, and this item is designed to close only after that review is recorded (the development build closes it on receipt).
Closes after: item 2, Clinician review of the received result: laboratory flag on ALT.
Already in the work queueItem 2 of 3: Result reviewClinician review of the received result: laboratory flag on ALTReview today
From the document
- Laboratory flagLab flag present
ALT 62 U/L — flagged H by the laboratory
Shown exactly as the laboratory reported it. Reedley does not interpret results.
Record Previous ALT: 38 U/L (14 Apr 2026), 34 U/L (21 Jul 2026).
Why Reedley says this The laboratory applied a flag to this value; the practice rule routes flagged results on a monitored medicine to a clinician.
Proposed work
Practice rule (draft): a laboratory flag on a medicine with shared-care monitoring goes to a clinician.
Verified when: A review entry recorded by a named clinician, with the date. Source: Clinical record, by design; simulated here.
Limit It shows that a review was recorded, not what it concluded. Reedley does not interpret results.
Reedley does not say what the result means or what to do. A clinician decides.
Reedley proposes; a named person decides. Nothing happens until you do.
Item 3 of 3: MonitoringNext methotrexate monitoring bloods (interval set by the clinician reviewing the ALT)Proposal
From the document
- Linked requestLinked to open work
Requested for methotrexate monitoring
Record Open item: methotrexate monitoring bloods (FBC, LFT, U&E) due 13 Oct, assigned to the admin team.
Why Reedley says this The clinical details on the request match an open monitoring item for this patient.
Proposed work
The shared-care schedule in this synthetic practice repeats every 12 weeks, but the next interval waits for the clinician reviewing the flagged ALT. The 12-week interval is a draft, unsigned rule.
Verified when: The next FBC, LFT and U&E received for this patient within the interval the reviewing clinician sets. Source: Pathology, by design; simulated here.
Monitoring intervals are designed to come from a rule a named clinician owns. Today the rule is an unsigned draft with no named owner.
Reedley proposes; a named person decides. Nothing happens until you do.
For information · no action proposed
- Haemoglobin, white cells, neutrophils, platelets, creatinineWithin the laboratory’s reference ranges, as reported. Shown for context, not interpreted.
What the record shows (synthetic)
Current medicines
- Methotrexate 2.5 mg tablets 15 mg once weekly (Friday) Shared care
- Folic acid 5 mg tablets Once weekly (not Friday) Repeat
Problems
Rheumatoid arthritis
Context
- Shared-care agreement
- Rheumatology, synthetic protocol v3 (illustrative)
- Monitoring rule
- FBC, LFT, U&E every 12 weeks (draft, unsigned)
- Previous ALT
- 38 U/L (14 Apr) · 34 U/L (21 Jul)
Work queue
1 open · 0 closed · Patricia LOWE
A person’s report moves an item to actioned; verification comes from the record where Reedley can read it; where it cannot, a named person’s structured statement is accepted today, and that rule is under review. Booked is not attended, sent is not read and issued is not taken.
- 1Monitoring due · already openVerified
Methotrexate monitoring bloods: FBC, LFT, U&E
- Identified, done
- Reviewed, done
- Assigned, done
- Actioned, done
- Verified, current step
- Closed, not reached
Verified when: All three panels received for this patient within the window. (Pathology)
- Proof · found 14 Oct 09:20 Pathology: FBC, LFT and U&E received 14 Oct 2026 09:12 for this patient (this report). (Simulated) The monitoring bloods were taken and reported.
Limit A received result is not a reviewed result. The laboratory flag goes to a clinician as its own item, and this item is designed to close only after that review is recorded (the development build closes it on receipt).
Evidence linked 14 Oct 09:20, from this document
Not yet: this item closes after “Clinician review of the received result: laboratory flag on ALT” is verified. Accept that proposal first.
History
Append-only. Who did what, when, and on what basis. Times are simulated.
Document received · Pathology report · Northfield Pathology (fictional)
Identity matched · Patricia LOWE
NHS number and date of birth on the report match the patient record.
Classified · Pathology result · Haematology and biochemistry
Laboratory report structure with three requested panels (p.1).
Identified · 3 findings, 2 proposals
Awaiting review by a named person.
Verified from source · Methotrexate monitoring bloods: FBC, LFT, U&E
Pathology: FBC, LFT and U&E received 14 Oct 2026 09:12 for this patient (this report). (Simulated) The monitoring bloods were taken and reported.
Verified from source · Methotrexate monitoring bloods: FBC, LFT, U&E
What the demonstration does not show
Real accuracy. These outputs were written in advance. They do not show how often the product extracts information correctly from real documents; that has not yet been measured.
Real integration. There is no connection to EMIS Web, SystmOne or any laboratory, and nothing is written to any record. “Source checks” are simulated to show how verification is meant to work once approved access exists.
Clinical rules. Intervals, routing rules and wording are illustrative. In the product, clinical rules are designed to be owned by named clinicians and versioned; today they are unsigned drafts with no named owner.